Enlivex (ENLV) Price & Analysis

Compare

461 Followers

ENLV Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.81 - $2.10

Previous CloseN/A

Volume59.48K

Average Volume (3M)797.14K

Market Cap

$24.57M

Enterprise Value$2.89M

Total Cash (Recent Filing)$19.51M

Total Debt (Recent Filing)$480.00K

Price to Earnings (P/E)―

Beta1.02

Next Earnings

May 23, 2025

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.72

Shares Outstanding23,858,301

10 Day Avg. Volume134,117

30 Day Avg. Volume797,137

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.12

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-7.77

Enterprise Value/Ebitda-0.20

Forecast

1Y Price Target

$7.00

Price Target Upside579.61% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsPositive three-month top-line data from the Phase 2a stage of a multi-center, two-stage Phase 1/2 double-blind, randomized, placebo-controlled clinical trial evaluating Allocetra™ in patients with moderate-to-severe knee OA were recently reported.

Intellectual PropertyEnlivex recently announced the issuance of an Israeli patent entitled 'Therapeutic Apoptotic Cells for Treatment of Osteoarthritis', providing added intellectual property protection in Israel through at least 2040.

Bears Say

Regulatory And Development ChallengesEnlivex is advancing Allocetra toward late-stage development with a planned roadmap of catalysts, including potential regulatory approval and dosing of the first patient in Phase 2b trial.

Enlivex News

Enlivex Therapeutics CEO issues letter to shareholders on Allocetra results

Enlivex Therapeutics (ENLV) issued the following update to shareholders from Chief Executive Officer, Oren Hershkovitz, highlighting the strength...

18d ago

ENLV

Enlivex Therapeutics announces issuance of Israeli patent for Allocetra

Enlivex Therapeutics (ENLV) announced the issuance of an Israeli patent, numbered 290470, titled, “THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT...

20d ago

ENLV

Enlivex Therapeutics Announces Annual General Meeting for November 2025

The latest announcement is out from Enlivex ( ($ENLV) ). Enlivex Therapeutics Ltd. announced that it will hold...

3d ago

ENLV

Enlivex’s Strategic Advancements and Patent Protection Drive Buy Rating for Osteoarthritis Treatment

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Enlivex today and set a price target of...

16d ago

ENLV

Enlivex Announces Positive Phase IIa Results for Allocetra™ in Knee Osteoarthritis

Enlivex ( ($ENLV) ) has shared an update. On September 11, 2025, Enlivex Therapeutics announced positive results from...

17d ago

ENLV

Enlivex Secures Israeli Patent for Osteoarthritis Treatment

An update from Enlivex ( ($ENLV) ) is now available. Enlivex Therapeutics Ltd. announced on September 9, 2025,...

20d ago

ENLV

Promising Potential of Enlivex’s Allocetra in Osteoarthritis: Buy Rating with $7 Price Target

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Enlivex, with a...

26d ago

ENLV

Enlivex Reports Financial Results for Mid-2025

Enlivex ( ($ENLV) ) has provided an update. On August 29, 2025, Enlivex Therapeutics Ltd. released its unaudited...

1M ago

ENLV

Enlivex’s Allocetra: A New Hope for Psoriatic Arthritis?

Enlivex Therapeutics (($ENLV)) announced an update on their ongoing clinical study. Enlivex Therapeutics is conducting a study titled...

1M ago

ENLV

Enlivex Therapeutics’ Phase 2 Study on Allocetra-OTS for Sepsis: Key Insights for Investors

Enlivex Therapeutics (($ENLV)) announced an update on their ongoing clinical study. Study Overview: Enlivex Therapeutics is conducting a...

1M ago

ENLV

Enlivex Therapeutics’ Phase 2 Study on Allocetra-OTS: A Promising Update for Sepsis Treatment

Enlivex Therapeutics (($ENLV)) announced an update on their ongoing clinical study. Enlivex Therapeutics recently updated its clinical study...

1M ago

ENLV

Enlivex Therapeutics Advances Psoriatic Arthritis Treatment with Allocetra Study

Enlivex Therapeutics (($ENLV)) announced an update on their ongoing clinical study. Study Overview: Enlivex Therapeutics is conducting a...

1M ago

ENLV

Enlivex Therapeutics announces topline data from Phase I/II trial of Allocetra

Enlivex Therapeutics (ENLV) announced three-month topline data from the Phase IIa stage of ENX-CL-05-001, a multi-center, two-stage Phase...

1M ago

ENLV

Enlivex to present 3-month data from Phase IIa osteoarthritis trial

Enlivex Therapeutics (ENLV) announced it will host a webinar on Monday, August 18, 2025 to present and discuss...

2M ago

ENLV

ENLV FAQ

What was Enlivex Therapeutics Ltd’s price range in the past 12 months?

Enlivex Therapeutics Ltd lowest stock price was $0.81 and its highest was $2.10 in the past 12 months.

What is Enlivex Therapeutics Ltd’s market cap?

Enlivex Therapeutics Ltd’s market cap is $24.57M.

When is Enlivex Therapeutics Ltd’s upcoming earnings report date?

Enlivex Therapeutics Ltd’s upcoming earnings report date is May 23, 2025 which is 129 days ago.

How were Enlivex Therapeutics Ltd’s earnings last quarter?

Enlivex Therapeutics Ltd released its earnings results on May 24, 2024. The company reported -$0.25 earnings per share for the quarter, the consensus estimate of -$0.25 by $0.

Is Enlivex Therapeutics Ltd overvalued?

According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Enlivex Therapeutics Ltd pay dividends?

Enlivex Therapeutics Ltd does not currently pay dividends.

What is Enlivex Therapeutics Ltd’s EPS estimate?

Enlivex Therapeutics Ltd’s EPS estimate is -0.15.

How many shares outstanding does Enlivex Therapeutics Ltd have?

Enlivex Therapeutics Ltd has 23,858,301 shares outstanding.

What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?

Enlivex Therapeutics Ltd reported an EPS of -$0.25 in its last earnings report, expectations of -$0.25. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?

Currently, no hedge funds are holding shares in ENLV

Enlivex Stock Smart Score

Neutral

Fundamentals

Return on Equity

-55.02%

Trailing 12-Months

Asset Growth

-29.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Enlivex Therapeutics Ltd

Enlivex (NASDAQ: ENLV) is a clinical-stage biopharmaceutical company engaged in the development of innovative immunotherapy treatments. The company is primarily focused on discovering and developing cell therapies designed to treat life-threatening conditions resulting from the overreaction of the immune system, such as sepsis and cancer. Enlivex's core product candidate is Allocetra, a cell therapy intended to modulate immune system responses and restore balance to the immune system.

Enlivex (ENLV) Earnings & Revenues

Historic Earnings Reports

ENLV Stock 12 Month Forecast

Average Price Target

$7.00

▲(579.61% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Sep<br/>2024","9":"Jan<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.06,1.516923076923077,1.9738461538461538,2.4307692307692306,2.8876923076923076,3.3446153846153845,3.801538461538461,4.258461538461538,4.715384615384615,5.172307692307692,5.6292307692307695,6.086153846153845,6.543076923076923,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.06,1.516923076923077,1.9738461538461538,2.4307692307692306,2.8876923076923076,3.3446153846153845,3.801538461538461,4.258461538461538,4.715384615384615,5.172307692307692,5.6292307692307695,6.086153846153845,6.543076923076923,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.06,1.516923076923077,1.9738461538461538,2.4307692307692306,2.8876923076923076,3.3446153846153845,3.801538461538461,4.258461538461538,4.715384615384615,5.172307692307692,5.6292307692307695,6.086153846153845,6.543076923076923,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.33,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.75,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >